

Pilar Martinez-Martinez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5262817/publications.pdf>

Version: 2024-02-01

93
papers

4,259
citations

126708

33
h-index

118652

62
g-index

98
all docs

98
docs citations

98
times ranked

5082
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies. <i>Frontiers in Immunology</i> , 2022, 13, 834342.	2.2	14
2	Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. <i>Autoimmunity Reviews</i> , 2022, 21, 103104.	2.5	7
3	Autoimmune Encephalitis With mGluR1 Antibodies Presenting With Epilepsy, but Without Cerebellar Signs. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, e1171.	3.1	4
4	FT-ICR Mass Spectrometry Imaging at Extreme Mass Resolving Power Using a Dynamically Harmonized ICR Cell with 1% or 2% Detection. <i>Analytical Chemistry</i> , 2022, 94, 9316-9326.	3.2	10
5	Function of ceramide transfer protein for biogenesis and sphingolipid composition of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	29
6	FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113240.	2.5	5
7	CERTL reduces C16 ceramide, amyloid- β^2 levels, and inflammation in a model of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 45.	3.0	16
8	The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens. <i>Schizophrenia Research</i> , 2021, 228, 462-471.	1.1	6
9	Screening for inborn errors of metabolism in psychotic patients using Next Generation Sequencing. <i>Journal of Psychiatric Research</i> , 2021, 138, 125-129.	1.5	1
10	Altered sphingolipid function in Alzheimer's disease; a gene regulatory network approach. <i>Neurobiology of Aging</i> , 2021, 102, 178-187.	1.5	8
11	Immunofluorescence Labeling of Lipid-Binding Proteins CERTs to Monitor Lipid Raft Dynamics. <i>Methods in Molecular Biology</i> , 2021, 2187, 327-335.	0.4	1
12	Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimer's Disease and Control Mice. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 765252.	1.7	7
13	Sphingolipids in Alzheimer's disease, how can we target them?. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 214-231.	6.6	53
14	Absence of Autoantibodies Against Neuronal Surface Antigens in Sera of Patients With Psychotic Disorders. <i>JAMA Psychiatry</i> , 2020, 77, 322.	6.0	8
15	Novel neuronal surface autoantibodies in plasma of patients with depression and anxiety. <i>Translational Psychiatry</i> , 2020, 10, 404.	2.4	10
16	Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer's disease transgenic mice by functioning as a metabolic probe. <i>Scientific Reports</i> , 2020, 10, 19354.	1.6	9
17	Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 232-244.	6.6	56
18	Unidentified Neuronal Surface IgG Autoantibodies in a Case of Hashimoto's Encephalopathy. <i>Frontiers in Immunology</i> , 2020, 11, 1358.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Autoimmune psychosis. <i>Lancet Psychiatry</i> , 2020, 7, 122-123.	3.7	7
20	Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. <i>Autoimmunity Reviews</i> , 2019, 18, 102348.	2.5	30
21	Rapid Visualization of Chemically Related Compounds Using Kendrick Mass Defect As a Filter in Mass Spectrometry Imaging. <i>Analytical Chemistry</i> , 2019, 91, 13112-13118.	3.2	31
22	Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2019, 9, 4908.	1.6	51
23	Astrocytic ceramide as possible indicator of neuroinflammation. <i>Journal of Neuroinflammation</i> , 2019, 16, 48.	3.1	50
24	Characterization of the thymus in Lrp4 myasthenia gravis: Four cases. <i>Autoimmunity Reviews</i> , 2019, 18, 50-55.	2.5	18
25	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. <i>JCI Insight</i> , 2019, 4, .	2.3	43
26	Anti-GAD antibodies in a cohort of neuropsychiatric patients. <i>Epilepsy and Behavior</i> , 2018, 82, 25-28.	0.9	10
27	Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder. <i>PLoS ONE</i> , 2018, 13, e0208412.	1.1	9
28	Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 769-781.	1.2	7
29	Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 795-807.	1.2	26
30	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. <i>Journal of Autoimmunity</i> , 2017, 77, 104-115.	3.0	92
31	Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 783-794.	1.2	11
32	Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. <i>Scientific Reports</i> , 2017, 7, 14426.	1.6	17
33	Activation of the NLRP3 inflammasome in microglia: the role of ceramide. <i>Journal of Neurochemistry</i> , 2017, 143, 534-550.	2.1	101
34	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. <i>Scientific Reports</i> , 2017, 7, 992.	1.6	10
35	Sphingolipids in Alzheimer's Disease and Related Disorders. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 753-756.	1.2	12
36	An in vitro and in vivo study of peptide-functionalized nanoparticles for brain targeting: The importance of selective blood-brain barrier uptake. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1289-1300.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?. <i>Frontiers in Immunology</i> , 2017, 8, 752.	2.2	14
38	Autoantibodies in Neuropsychiatric Disorders. <i>Antibodies</i> , 2016, 5, 9.	1.2	22
39	Silencing of Dok-7 in Adult Rat Muscle Increases Susceptibility to Passive Transfer Myasthenia Gravis. <i>American Journal of Pathology</i> , 2016, 186, 2559-2568.	1.9	12
40	Titin antibodies in "seronegative" myasthenia gravis" A new role for an old antigen. <i>Journal of Neuroimmunology</i> , 2016, 292, 108-115.	1.1	57
41	TrkB in the hippocampus and nucleus accumbens differentially modulates depression-like behavior in mice. <i>Behavioural Brain Research</i> , 2016, 296, 15-25.	1.2	22
42	Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII ± 1 Chain. <i>American Journal of Human Genetics</i> , 2015, 97, 878-885.	2.6	57
43	Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model"Recommendations for methods and experimental designs. <i>Experimental Neurology</i> , 2015, 270, 3-10.	2.0	25
44	MuSK autoantibodies in myasthenia gravis detected by cell based assay " A multinational study. <i>Journal of Neuroimmunology</i> , 2015, 284, 10-17.	1.1	63
45	Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells. <i>Journal of Visualized Experiments</i> , 2015, , e52830.	0.2	5
46	Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 731.	6.0	58
47	Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with <i>Torpedo californica</i> acetylcholine receptors " Recommendations for methods and experimental designs. <i>Experimental Neurology</i> , 2015, 270, 18-28.	2.0	51
48	Detection of Peptide-Based Nanoparticles in Blood Plasma by ELISA. <i>PLoS ONE</i> , 2015, 10, e0126136.	1.1	4
49	Glycine receptor antibodies in PERM: a new channelopathy. <i>Brain</i> , 2014, 137, 2115-2116.	3.7	3
50	Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis Patients. <i>Journal of Immunology</i> , 2014, 193, 1055-1063.	0.4	45
51	Delivery of DNA into the Central Nervous System via Electroporation. <i>Methods in Molecular Biology</i> , 2014, 1121, 157-163.	0.4	3
52	Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. <i>Journal of Autoimmunity</i> , 2014, 52, 101-112.	3.0	41
53	A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. <i>Journal of Autoimmunity</i> , 2014, 52, 139-145.	3.0	244
54	Complement Activation by Ceramide Transporter Proteins. <i>Journal of Immunology</i> , 2014, 192, 1154-1161.	0.4	21

#	ARTICLE	IF	CITATIONS
55	Fetal asphyctic preconditioning modulates the acute cytokine response thereby protecting against perinatal asphyxia in neonatal rats. <i>Journal of Neuroinflammation</i> , 2013, 10, 14.	3.1	19
56	Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2013, 261, 141-145.	1.1	12
57	Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. <i>Autoimmunity Reviews</i> , 2013, 12, 918-923.	2.5	143
58	The effects of fetal and perinatal asphyxia on neuronal cytokine levels and ceramide metabolism in adulthood. <i>Journal of Neuroimmunology</i> , 2013, 255, 97-101.	1.1	12
59	Ceramide function in the brain: when a slight tilt is enough. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 181-203.	2.4	192
60	Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 261, 98-107.	1.1	6
61	Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. <i>Annals of Neurology</i> , 2013, 73, 281-293.	2.8	73
62	Fetal asphyxia induces acute and persisting changes in the ceramide metabolism in rat brain. <i>Journal of Lipid Research</i> , 2013, 54, 1825-1833.	2.0	6
63	Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders. <i>Frontiers in Genetics</i> , 2013, 4, 181.	1.1	14
64	Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques. <i>Journal of Biological Chemistry</i> , 2012, 287, 14897-14911.	1.6	31
65	Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. <i>Brain</i> , 2012, 135, 1081-1101.	3.7	180
66	Unchanged expression of the ceramide transfer protein in the acute 6-OHDA neurodegenerative model. <i>Neuroscience Letters</i> , 2012, 506, 39-43.	1.0	1
67	MuSK myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 795-797.	0.6	10
68	Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 48-59.	1.8	34
69	Neuropathy-Induced Spinal GAP-43 Expression Is Not a Main Player in the Onset of Mechanical Pain Hypersensitivity. <i>Journal of Neurotrauma</i> , 2011, 28, 2463-2473.	1.7	16
70	Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2011, 232, 158-165.	1.1	7
71	Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis. <i>Journal of Immunology</i> , 2011, 186, 2503-2513.	0.4	115
72	Paradoxical Increase in TAG and DAG Content Parallel the Insulin Sensitizing Effect of Unilateral DGAT1 Overexpression in Rat Skeletal Muscle. <i>PLoS ONE</i> , 2011, 6, e14503.	1.1	39

#	ARTICLE	IF	CITATIONS
73	The ceramide transporter and the Goodpasture antigen binding protein: one protein â€“ one function?. <i>Journal of Neurochemistry</i> , 2010, 113, 1369-1386.	2.1	33
74	Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. <i>Molecular Therapy</i> , 2010, 18, 1183-1191.	3.7	31
75	A novel method for making human monoclonal antibodies. <i>Journal of Autoimmunity</i> , 2010, 35, 130-134.	3.0	36
76	In vivo electroporation of the central nervous system: A non-viral approach for targeted gene delivery. <i>Progress in Neurobiology</i> , 2010, 92, 227-244.	2.8	66
77	The auto-antigen repertoire in myasthenia gravis. <i>Autoimmunity</i> , 2010, 43, 380-400.	1.2	48
78	Antibody effector mechanisms in myasthenia gravisâ€™ Pathogenesis at the neuromuscular junction. <i>Autoimmunity</i> , 2010, 43, 353-370.	1.2	101
79	Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. <i>Neurobiology of Disease</i> , 2009, 35, 14-23.	2.1	15
80	B cell characterization and reactivity analysis in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2009, 8, 654-658.	2.5	47
81	Delivery of peptide and protein drugs over the bloodâ€™brain barrier. <i>Progress in Neurobiology</i> , 2009, 87, 212-251.	2.8	245
82	The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain. <i>Journal of Chemical Neuroanatomy</i> , 2009, 38, 97-105.	1.0	9
83	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. <i>American Journal of Pathology</i> , 2009, 175, 1536-1544.	1.9	37
84	<i>Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 174-179.	1.8	19
85	Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 111-120.	1.1	17
86	Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization. <i>Journal of Pharmacological and Toxicological Methods</i> , 2008, 58, 27-31.	0.3	11
87	Goodpasture Antigen-binding Protein Is a Soluble Exportable Protein That Interacts with Type IV Collagen. <i>Journal of Biological Chemistry</i> , 2008, 283, 30246-30255.	1.6	26
88	Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis. <i>American Journal of Pathology</i> , 2007, 170, 644-657.	1.9	33
89	Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. <i>Science</i> , 2007, 317, 1554-1557.	6.0	846
90	A human-specific TNF-responsive promoter for Goodpasture antigen-binding protein. <i>FEBS Journal</i> , 2005, 272, 5291-5305.	2.2	16

#	ARTICLE	IF	CITATIONS
91	DCAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content. <i>Journal of Lipid Research</i> , 2005, 46, 230-236.	2.0	41
92	Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. <i>Brain</i> , 2005, 128, 2327-2337.	3.7	66
93	Goodpasture Antigen-binding Protein, the Kinase That Phosphorylates the Goodpasture Antigen, Is an Alternatively Spliced Variant Implicated in Autoimmune Pathogenesis. <i>Journal of Biological Chemistry</i> , 2000, 275, 40392-40399.	1.6	69